Datatruck | $12,000,000 | (Jan 29, 2026)
Vention | $110,000,000 | (Jan 29, 2026)
Tenbin Labs | $7,000,000 | (Jan 29, 2026)
Certified by Founder
Lodge
Glycomine Inc.
start up
United States
- San Carlos, California
- 17/04/2025
- Series C
- $115,000,000
Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. Glycomine’s lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.
- Industry Biotechnology Research
- Website https://www.glycomine.com/
- LinkedIn https://www.linkedin.com/company/glycomine-inc-/
Related People
Steven AxonFounder
United States -
Cohasset, Massachusetts
Specialties: Biotech, Business Development,
Corporate Strategy, Corporate Finance, Alliance Management
Oro(US) | $3,000,000 | (Jan 29, 2026)
Yolando | $8,500,000 | (Jan 29, 2026)
Origin(US) | Undisclosed Amount | (Jan 29, 2026)
Gyde | $60,000,000 | (Jan 29, 2026)
Limy AI | $10,000,000 | (Jan 29, 2026)
Scholé AI | $3,000,000 | (Jan 29, 2026)
Emobi | $3,400,000 | (Jan 29, 2026)
Adaptive6 | $28,000,000 | (Jan 29, 2026)
Fiddler AI | $30,000,000 | (Jan 28, 2026)